Improved ziprasidone formulations with enhanced bioavailability in the fasted state and a reduced food effect

Pharmaceutical Research

Volumn 28, Issue 12, 2011, Pages 3159-3170

  Thombre, Avinash G ^a   Herbig, Scott M ^a   Alderman, Jeffrey A ^a  

^a PFIZER INC   (United States)

Author keywords

food effect; solubilization; ziprasidone

Indexed keywords

BETA CYCLODEXTRIN SULFOBUTYL ETHER; HYDROXYPROPYLMETHYLCELLULOSE; METHACRYLIC ACID; ZIPRASIDONE;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CALORIC INTAKE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DISPERSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DOSAGE FORM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG SOLUBILITY; DRUG TOLERABILITY; EVENING DOSAGE; FOOD; FOOD DRUG INTERACTION; FREEZE DRYING; HUMAN; HUMAN EXPERIMENT; LIPID DIET; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NANOSUSPENSION; NORMAL HUMAN; OPEN STUDY; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SIMULATION; SINGLE DRUG DOSE; SPRAY DRYING; STEADY STATE;

AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DOPAMINE ANTAGONISTS; EXCIPIENTS; FASTING; FOOD-DRUG INTERACTIONS; HUMANS; PIPERAZINES; SOLUBILITY; THIAZOLES;

EID: 83555174462     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-011-0505-7     Document Type: Article

References (46)

1. WM Greenberg L Citrome 2007 Ziprasidone for schizophrenia and bipolar disorder: a review of the Clinical trials CNS Drug Rev 13 2 137 77 17627670 10.1111/j.1527-3458.2007.00008.x 1:CAS:528:DC%2BD2sXpsVCltb4%3D (Pubitemid 47052346)
2. NC Patel PE Keck Jr 2006 Ziprasidone: efficacy and safety in patients with bipolar disorder Expert Rev Neurother 6 8 1129 38 16893341 10.1586/14737175.6.8.1129 1:CAS:528:DC%2BD28Xps1Cqtbg%3D (Pubitemid 44231971)
3. JJ Miceli KD Wilner RA Hansen AC Johnson G Apseloff N Gerber 2000 Single- and multiple-dose pharmacokinetics of ziprasidone under nonfasting conditions in healthy male volunteers Br J Clin Pharmacol 49 Suppl. 1 5S 13 10771448 1:CAS:528:DC%2BD3cXis1egsrw%3D
4. J Lincoln E Stewart Mark H Preskorn Sheldon 2010 How sequential studies inform drug development: evaluating the effect of food intake on optimal bioavailability of ziprasidone J Psychiatr Pract 16 2 103 14 20511734 10.1097/01.pra.0000369971.64908.dc
5. J Miceli Jeffrey P Glue J Alderman K Wilner 2007 The effect of food on the absorption of oral ziprasidone Psychopharmacol Bull 40 3 58 68 18007569 1:STN:280:DC%2BD2snotFaktw%3D%3D
6. K Gandelman JA Alderman P Glue I Lombardo RR La Badie M Versavel, et al. 2009 The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial J Clin Psychiat (Memphis, TN, United States) 70 1 58 62 1:CAS:528:DC%2BD1MXivVGkt7Y%3D
7. BA Hamelin S Allard L Laplante J Miceli KD Wilner J Tremblay, et al. 1998 The effect of timing of a standard meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic agent ziprasidone Pharmacotherapy 18 1 9 15 9469675 1:CAS:528:DyaK1cXpt1ymuw%3D%3D (Pubitemid 28058997)
8. L Citrome 2009 Using oral ziprasidone effectively: the food effect and dose-response Adv Ther 26 8 739 48 19669631 10.1007/s12325-009-0055-0 1:CAS:528:DC%2BD1MXhtFOrtbzM
9. A Fagiolini F Canas B Gallhofer I Larmo P Levy JM Montes, et al. 2010 Strategies for successful clinical management of schizophrenia with ziprasidone Expert Opin Pharmacother 11 13 2199 220 20658947 10.1517/14656566.2010.507630 1:CAS:528:DC%2BC3cXhtVansbfN
10. Geodon [U.S. Prescribing Information including Patient Summary of Information] P, Inc., Revised Nov. 2009.
11. O Perkins Diana 2002 Predictors of noncompliance in patients with schizophrenia J Clin Psychiatr 63 12 1121 8 10.4088/JCP.v63n1206 1:STN:280:DC%2BD3s%2Fhsl2gtA%3D%3D
12. PD Harvey CR Bowie 2005 Ziprasidone: efficacy, tolerability, and emerging data on wide-ranging effectiveness Expert Opin Pharmacother 6 2 337 46 15757429 10.1517/14656566.6.2.337 1:CAS:528:DC%2BD2MXhsFSmsrY%3D (Pubitemid 40305345)
13. PG Welling 1996 Effects of food on drug absorption Annu Rev Nutr 16 383 415 8839932 10.1146/annurev.nu.16.070196.002123 1:CAS:528:DyaK28XksFKru7w%3D
14. BN Singh 1999 Effects of food on clinical pharmacokinetics Clin Pharmacokinet 37 3 213 55 10511919 10.2165/00003088-199937030-00003 1:CAS:528:DyaK1MXmsFKrsL0%3D (Pubitemid 29452756)
15. VJ Stella KW Nti-Addae 2007 Prodrug strategies to overcome poor water solubility Adv Drug Deliv Rev 59 7 677 94 17628203 10.1016/j.addr.2007.05.013 1:CAS:528:DC%2BD2sXpsFGksL8%3D (Pubitemid 47285410)
16. D Fleisher R Bong BH Stewart 1996 Improved oral drug delivery: solubility limitations overcome by the use of prodrugs Adv Drug Deliv Rev 19 2 115 30 10.1016/0169-409X(95)00103-E 1:CAS:528:DyaK28XjtFaksbc%3D (Pubitemid 26192965)
17. ATM Serajuddin 2007 Salt formation to improve drug solubility Adv Drug Deliv Rev 59 7 603 16 17619064 10.1016/j.addr.2007.05.010 1:CAS:528: DC%2BD2sXpsFGksrc%3D (Pubitemid 47285406)
18. N Blagden M de Matas PT Gavan P York 2007 Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates Adv Drug Deliv Rev 59 7 617 30 17597252 10.1016/j.addr.2007.05.011 1:CAS:528: DC%2BD2sXpsFGks7w%3D (Pubitemid 47285407)
19. CJH Porter CW Pouton JF Cuine WN Charman 2008 Enhancing intestinal drug solubilization using lipid-based delivery systems Adv Drug Deliv Rev 60 6 673 91 18155801 10.1016/j.addr.2007.10.014 1:CAS:528:DC%2BD1cXitVOmsr4%3D
20. J-l Tang J Sun Z-G He 2007 Self-emulsifying drug delivery systems: strategy for improving oral delivery of poorly soluble drugs Curr Drug Ther 2 1 85 93 10.2174/157488507779422400 1:CAS:528:DC%2BD2sXhvVantbY%3D (Pubitemid 46723141)
21. AJ Humberstone WN Charman 1997 Lipid-based vehicles for the oral delivery of poorly water soluble drugs Adv Drug Deliv Rev 25 1 103 28 10.1016/S0169-409X(96)00494-2 1:CAS:528:DyaK2sXhtlOqs70%3D
22. ME Brewster T Loftsson 2007 Cyclodextrins as pharmaceutical solubilizers Adv Drug Deliv Rev 59 7 645 66 17601630 10.1016/j.addr.2007.05.012 1:CAS:528:DC%2BD2sXpsFGks7g%3D (Pubitemid 47299263)
23. E Merisko-Liversidge GG Liversidge ER Cooper 2003 Nanosizing: a formulation approach for poorly-water-soluble compounds Eur J Pharm Sci 18 2 113 20 12594003 10.1016/S0928-0987(02)00251-8 1:CAS:528:DC%2BD3sXht1Kltrg%3D (Pubitemid 36184748)
24. F Kesisoglou S Panmai Y Wu 2007 Nanosizing-Oral formulation development and biopharmaceutical evaluation Adv Drug Deliv Rev 59 7 631 44 17601629 10.1016/j.addr.2007.05.003 1:CAS:528:DC%2BD2sXpsFGks7o%3D (Pubitemid 47285408)
25. DT Friesen R Shanker M Crew DT Smithey WJ Curatolo JAS Nightingale 2008 Hydroxypropyl methylcellulose acetate succinate-based spray-dried dispersions: an overview Mol Pharm 5 6 1003 19 19040386 10.1021/mp8000793 1:CAS:528:DC%2BD1cXhsVSntb3F
26. Shah JC. Novel injectable depot formulations of heterocyclic aryl compounds. Application: WO. WO patent 2003-IB4576 2004037289. 2004 20031013
27. Shah JC, Shah PS, Wisniecki P, Wagner DR. Injectable depot formulations and methods for providing sustained release of nanoparticle compositions. Application: US. US patent 2008-43014 2008305161. 2008 20080305
28. Babcock WC, Caldwell WB, Crew MD, Friesen DT, Smithey DT, Shanker RM. Pharmaceutical compositions of semi-ordered drugs and polymers. Application: WO.WO patent 2003-IB3465 2004014342. 2004 20030731.
29. JS Janiszewski HG Fouda RO Cole 1995 Development and validation of a high-sensitivity assay for an antipsychotic agent, CP-88,059, with solid-phase extraction and narrow-bore high-performance liquid chromatography J Chromatogr B Biomed Appl 668 1 133 9 7550970 10.1016/0378-4347(95)00071-P 1:CAS:528:DyaK2MXlvFKnu7Y%3D
30. Phase I Study to Access the Safety, Toleration, and Pharmacokinetics of CP-88,059-1 Following Escalating Single Oral Doses under Fasting and Non-fasting conditions in Normal Healthy Male Volunteers, Pfizer Inc. 1996
31. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry; Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations, March, 2003
32. AW Boddy FC Snikeris RO Kringle GCG Wei JA Oppermann KK Midha 1995 An approach for widening the bioequivalence acceptance limits in the case of highly variable drugs Pharm Res 12 12 1865 8 8786957 10.1023/A:1016219317744 1:CAS:528:DyaK28Xis1yqtw%3D%3D (Pubitemid 26032293)
33. E Diletti D Hauschke VW Steinijans 1992 Sample size determination: extended tables for the multiplicative model and bioequivalence ranges of 0.9 to 1.11 and 0.7 to 1.43 Int J Clin Pharmacol Ther Toxicol 30 Suppl 1 S59 62 1601533
34. WW Hauck A Parekh LJ Lesko ML Chen RL Williams 2001 Limits of 80%-125% for AUC and 70%-143% for Cmax. What is the impact on bioequivalence studies? Int J Clin Pharmacol Ther 39 8 350 5 11515710 1:CAS:528:DC%2BD38XlsValtg%3D%3D (Pubitemid 32707813)
35. V Karalis P Macheras M Symillides 2005 Geometric mean ratio-dependent scaled bioequivalence limits with leveling-off properties Eur J Pharm Sci 26 1 54 61 15955680 10.1016/j.ejps.2005.04.019 1:CAS:528:DC%2BD2MXntVGjs74%3D (Pubitemid 41097261)
36. J Kytariolos V Karalis P Macheras M Symillides 2006 Novel scaled bioequivalence limits with leveling-off properties Pharm Res 23 11 2657 64 17048119 10.1007/s11095-006-9107-1 1:CAS:528:DC%2BD28XhtFKgu7bK (Pubitemid 44691612)
37. L Tothfalusi L Endrenyi KK Midha 2003 Scaling or wider bioequivalence limits for highly variable drugs and for the special case of Cmax Int J Clin Pharmacol Ther 41 5 217 25 12776813 1:CAS:528:DC%2BD3sXlsFeltro%3D (Pubitemid 36603765)
38. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. DRAFT Guidance for Food Effect Bioavailability and Bioequivalence Studies (December, 1997)
39. J Miceli S Preskorn K Wilner C Folger T Tensfeldt 1998 Characetrization of the intramuscular pharmacokinetics of ziprasidone in schizophrenic patients Eur Psychiatry 13 suppl 4 304S 5 10.1016/S0924-9338(99)80614-2
40. D Taylor 2003 Ziprasidone in the management of schizophrenia: the QT interval issue in context CNS Drugs 17 6 423 30 12697001 10.2165/00023210- 200317060-00004 1:CAS:528:DC%2BD3sXksVahu7c%3D (Pubitemid 36560704)
41. DG Daniel 2003 Tolerability of ziprasidone: an expanding perspective J Clin Psychiatry 64 Suppl. 19 40 9 14728089 1:CAS:528:DC%2BD2cXnslelsQ%3D%3D
42. JJ Miceli TG Tensfeldt T Shiovitz RJ Anziano C O'Gorman RH Harrigan 2010 Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder Clin Ther 32 3 472 91 20399985 10.1016/j.clinthera.2010.03.003 1:CAS:528:DC%2BC3cXosVWqu7c%3D
43. L Citrome A Jaffe J Levine 2009 How dosing of ziprasidone in a state hospital system differs from product labeling J Clin Psychiat (Memphis, TN, United States) 70 7 975 82 1:CAS:528:DC%2BD1MXhsFentbnN
44. O Levy Woodburne R Robichaux-Keene Nicole C Nunez 2004 No significant QTc interval changes with high-dose ziprasidone: a case series J Psychiatr Pract 10 4 227 32 15552544 10.1097/00131746-200407000-00003 1:STN:280: DC%2BD2crns1agug%3D%3D (Pubitemid 38988937)
45. A Deutschman Daniel H Deutschman Douglas 2007 High-dose ziprasidone in treatment-resistant schizophrenia and affective spectrum disorders: a case series J Clin Psychopharmacol 27 5 513 4 17873687 10.1097/JCP.0b013e31814cface 1:STN:280:DC%2BD2srpsVWrsA%3D%3D (Pubitemid 47415053)
46. JJ Miceli KD Wilner SK Swan TG Tensfeldt 2005 Pharmacokinetics, safety, and tolerability of intramuscular Ziprasidone in healthy volunteers J Clin Pharmacol 45 6 620 30 15901743 10.1177/0091270005276485 1:CAS:528: DC%2BD2MXlsFSltrg%3D (Pubitemid 40696204)